title: [Effect of lymphokine activated killer from umbilical blood on human ovarian cancer in nude mouse models].
abstract: OBJECTIVE
  To explore the possibility of using lymphokine activated killer (LAK) from cord blood as an adoptive immunotherapy for ovarian cancer.
  
  
  METHODS
  The nude mouse models with human ovarian cancer were treated with the LAK from cord blood and compared with those treated with the LAK from the pheripheral blood.
  
  
  RESULTS
  The LAK from the cord blood inhibited the growth of human ovarian cancer. The average size of the tumor was 6.0 mm3 23 days after the cord blood LAK treatment, with an average weight of (0.674 +/- 0.45 g).
  
  
  CONCLUSIONS
  Cord blood can be a source of adoptive cellular immunotherapy for the treatment of ovarian cancer.
authors.affiliation: Department of Obsterics and Gynecology, West China Second Hospital, Sichuan University, Chengdu 610041, China.
authors.forename: Yue-dong
authors.initials: YD
authors.lastname: He
authors.forename: Zhi-lan
authors.initials: ZL
authors.lastname: Peng
authors.forename: Shan-ling
authors.initials: SL
authors.lastname: Liu
authors.forename: He
authors.initials: H
authors.lastname: Wang
authors.forename: Xiao-ling
authors.initials: XL
authors.lastname: Pan
mesh_terms: D000818:Animals; D045744:Cell Line, Tumor; D005260:Female; D005312:Fetal Blood / Q000166:cytology* / Q000276:immunology; D006801:Humans; D016219:Immunotherapy, Adoptive; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D010051:Ovarian Neoplasms / Q000276:immunology / Q000628:therapy*